Abemaciclib: Interim Phase III data

Eli Lilly said it will continue the double-blind, placebo-controlled, international Phase III MONARCH 2 trial without modification on the recommendation of an IDMC despite a preplanned interim analysis of 669 postmenopausal women with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer showing that twice-daily 150 mg oral abemaciclib plus Faslodex fulvestrant did not meet efficacy criteria. The trial enrolled patients who had disease progression on or within 12 months of receiving endocrine treatment in the neoadjuvant or adjuvant setting or while receiving first-line endocrine therapy for metastatic disease. ...